Taysha Gene Therapies (TSHA) Return on Sales (2022 - 2025)

Historic Return on Sales for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to 14.92%.

  • Taysha Gene Therapies' Return on Sales fell 16000.0% to 14.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 14.92%, marking a year-over-year decrease of 67100.0%. This contributed to the annual value of 10.15% for FY2024, which is 53700.0% down from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Return on Sales is 14.92%, which was down 16000.0% from 12.54% recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Return on Sales registered a high of 74.86% during Q1 2022, and its lowest value of 17.88% during Q2 2024.
  • Over the past 4 years, Taysha Gene Therapies' median Return on Sales value was 6.64% (recorded in 2024), while the average stood at 5.52%.
  • Per our database at Business Quant, Taysha Gene Therapies' Return on Sales plummeted by -786100bps in 2023 and then soared by 53400bps in 2025.
  • Quarter analysis of 4 years shows Taysha Gene Therapies' Return on Sales stood at 42.2% in 2022, then tumbled by -110bps to 4.17% in 2023, then crashed by -116bps to 9.03% in 2024, then tumbled by -65bps to 14.92% in 2025.
  • Its Return on Sales was 14.92% in Q3 2025, compared to 12.54% in Q2 2025 and 8.74% in Q1 2025.